A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Antinuclear Antibodies (ANA)
MessageSendout, Mayo test code: ANA2
Test Code
LAB147
Alias/See Also
ANA1
ANA2
Antinuclear Antibody, Serum
Hep-2
ANA (order test ANA2)
ANA (Antinuclear Antibodies)
Antinuclear Antibodies (ANA), HEp-2 substrate, Serum
LE (Lupus Erythematosus) Prep
ANA Screen
ANA
ANA2
Antinuclear Antibody, Serum
Hep-2
ANA (order test ANA2)
ANA (Antinuclear Antibodies)
Antinuclear Antibodies (ANA), HEp-2 substrate, Serum
LE (Lupus Erythematosus) Prep
ANA Screen
ANA
CPT Codes
86038
Preferred Specimen
0.5 mL serum from a gold serum gel tube
Minimum Volume
0.4 mL
Other Acceptable Specimens
Red tube
Instructions
Centrifuge and aliquot serum into a plastic vial.
Transport Container
Plastic vial
Transport Temperature
Refrigerated
Specimen Stability
Refrigerated (preferred): 21 days
Frozen: 21 days
Frozen: 21 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Gross hemolysis: Reject
Gross lipemia: Reject
Gross icterus: OK
Gross lipemia: Reject
Gross icterus: OK
Methodology
Enzyme-Linked Immunosorbent Assay (ELISA)
FDA Status
Approved
Setup Schedule
Monday through Saturday
Report Available
1 day
Limitations
Results for antinuclear antibodies (ANA) performed by enzyme-linked immunosorbent assay (ELISA) and traditional immunofluorescence assay (IFA) in the Mayo Clinic Antibody Immunology Laboratory show both methods to be substantially equivalent for the evaluation of common connective tissue diseases (CTD); systemic lupus erythematosus, Sjogren syndrome, and mixed connective tissue disease.(2) Negative results do not rule out the diagnosis of other CTD, such as systemic sclerosis and inflammatory myopathies, and overlap syndromes associated with complex antigens optimally detected in with the ANA IFA and associated with nucleolar, certain cytoplasmic and/or speckled patterns. For autoimmune hepatitis and juvenile idiopathic arthritis, ANA IFA remains the optimal testing method as the target autoantigens are largely unknown and not included in the ELISA or other solid-phase immunoassays.(3-6)
ANA may also be detectable following viral illnesses, in individuals with chronic infections, or in patients treated with many different medications.
ANA may also be detectable following viral illnesses, in individuals with chronic infections, or in patients treated with many different medications.
Reference Range
Included with report
Clinical Significance
Evaluating patients at-risk for antinuclear antibodies-associated systemic autoimmune rheumatic disease particularly systemic lupus erythematosus, Sjogren syndrome, and mixed connective tissue disease
Performing Laboratory
Mayo Clinic Laboratories, Rochester, Minnesota
Additional Information
Antinuclear Antibodies (ANA), Serum